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The use of biopharmaceuticals dates from the 19th century and within 5–10 years, up to
50% of all drugs in development will be biopharmaceuticals. In the 1980s, the biophar-
maceutical industry experienced a signiﬁcant growth in the production and approval of
recombinant proteins such as interferons (IFN , , and ) and growth hormones. The pro-
duction of biopharmaceuticals, known as bioprocess, involves a wide range of techniques. In
this  review, we discuss the technology involved in the bioprocess and describe the available
strategies and main advances in microbial fermentation and puriﬁcation process to obtain
biopharmaceuticals.
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Introduction
Biopharmaceuticals are mostly therapeutic recombinant pro-
teins obtained by biotechnological processes. They are derived
from biological sources such as organs and tissues, microor-
ganisms, animal ﬂuids, or genetically modiﬁed cells and
organisms.1,2 Although several different expression systems
may be employed including mammalian cell lines, insects,
and plants, new technological advancements are contin-
uously being made to improve microorganism production
of biopharmaceuticals. This investment is justiﬁed by the
well-characterized genomes, versatility of plasmid vectors,
availability of different host strains, cost-effectiveness as com-
pared with other expression systems.2,3
Bioprocessing is a crucial part of biotechnology. There is an
anticipation that within the next 5 to 10 years, up to 50% of all
drugs in development will be biopharmaceuticals. Examples
include recombinant proteins obtained through microbial fer-
mentation process.2,3 Bioprocessing for biopharmaceuticals
production involves a wide range of techniques. In this review,
we describe the main advances in microbial fermentation and
puriﬁcation process to obtain biopharmaceuticals.
Biopharmaceuticals  and  the  pharmaceutical  industry
Drug development is an extremely complex and expensive
process. According to the Tufts Center for the Study of
Drug Development4 (http://www.csdd.tufts.edu), it may take
approximately 15 years of intense research from the ini-
tial idea to the ﬁnal product and development and costs
usually exceed $2 billion. Low-molecular mass molecules
are generically named as drugs while high-molecular mass
drugs, which are represented by polymers of nucleotides (RNA
or DNA) or amino acids (peptides and proteins), are called
biopharmaceuticals.5 Biopharmaceuticals based in nucleic
acids, such as small interfering RNA (siRNA), DNA vaccines,
and gene therapy, are very promising strategies. However, clin-
ical protocols were approved only very recently6 and just a
few nucleic acids-based drugs have been therapeutically used
to date7 and recent reviews addressed the state of the art of
nucleic acids in therapies.8,9 In this review, we  focused on pep-
tides and proteins because they represent the major class of
biopharmaceuticals.10
The use of proteins as drugs has been highlighted mainly
by the high versatility of these biomolecules, which have dif-
ferent physiological roles in the human body including as
catalysts, receptors, membrane channels, macromolecule car-
riers, and cellular defense agents.10,11 Some protein therapies
provide high speciﬁcity, such as replacement of a patient’s
defective protein or even fulﬁll its absence due to genetic
defects or immunological complications.10
Biopharmaceuticals:  reference,  biosimilars,  and  biobetters
It is worth emphasizing that the same gene product, which
encodes the identical amino acid sequence, could be obtained
by extraction from an animal tissue or by recombinant DNA
techniques. However, the same protein produced by differ-
ent manufacturers present different characteristics. In order b i o l o g y 4 7 S (2 0 1 6) 51–63
to differentiate the products, the ﬁrst biopharmaceutical
version of the same therapeutic protein is set as the refer-
ence medicine, whereas the following ones are denominated
biosimilars. Biosimilars may present differences because
of post-translational modiﬁcations (phosphorylation, glyco-
sylation) and different manufacturing processes. The term
biobetter, also named biosuperiors, was recently used to refer
to therapeutic macromolecules of the next generation, which
present more  effective drug delivery system, are modiﬁed
by chemical methods (e.g., PEGylation) and/or engineered
by means of molecular biology techniques to present better
pharmacologic properties such as higher activity, enhanced
stability, fewer side effects, and lower immunogenicity.12,13
Therefore, while a biosimilar represents a generic version
of the original biopharmaceutical, biobetters need original
research and development and the costs are signiﬁcantly
higher.14
Additionally, while the ﬁrst biopharmaceuticals were pre-
dominantly delivered by injections, biobetters adopt different
approaches to drug delivery administration as oral, derma-
tological and inhaled formulations which are related with
different encapsulation approaches aiming to minimize the
biologic instability caused by protein aggregation and dena-
turation as consequence of physicochemical modiﬁcations
processes of the biodrug as deamination, hydrolysis, oxi-
dation, among others.15 Protein engineering and rational
modiﬁcation is also a very promising area in new biopharma-
ceuticals and some aspects will be discussed later.
The use of biopharmaceuticals has grown worldwide in the
last few years. In 2016, the total number of products approved
by the Foods and Drugs Administration (FDA) and European
Medicines Agency (EMA) for use in humans reached 1357, of
which >130 have different formulations (reference products),
737 are biosimilars, and the remaining 482 are classiﬁed as
biobetters16 (http://www.biopharma.com). From 2013 to 2016,
73 biopharmaceuticals were approved for use in humans.
Among them, high prominence was given to monoclonal
antibodies (23 approvals) widely used in several diagnostic
procedures, treatment of inﬂammatory diseases, and neoplas-
tic tumors16 (http://www.biopharma.com).
In addition, the European Medicine Agency (EMA) licensed
two  new products based on gene therapy (insertion of a
corrective gene able to produce a normal protein in the
patient’s genome to cure a genetic disease) for use in human
therapeutic protocols. These products were Glybera, devel-
oped by the German company UniQure for the treatment
of lipoprotein lipase deﬁciency, and Strimvelis, developed by
GlaxoSmithKline (GSK) for the treatment of adenosine deam-
inase deﬁciency.17 Although biopharmaceuticals can be very
effective for disease control or cure, treatment costs can reach
up to $1 million per patient.18
Biobetters  based  in  protein  structure  engineering
One of the most promising areas of the biobetters relies in
protein structure engineering aiming the development of bio-
drugs with better pharmacological properties including higher
activity, fewer side effects, and lower immunogenicity. The
breakthrough in the determination of protein structures and
their use as medicines dates from 1980s as a consequence
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3D structure determination
Structural analysis at atomic level
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Fig. 1 – Pipeline of protein engineering to obtain biobetters.
The protein is represented by molecular surface and
colorized by coulombic forces (blue = positive,
red = negative, and white = neutral).b r a z i l i a n j o u r n a l o f m i 
f the advances in recombinant DNA technology. In turn,
tructural biochemistry has revolutionized our understand-
ng of protein biology and afforded the beginning of protein
ngineering processes that can create protein drugs that are
ore  effective than wild type proteins. Protein engineering
ay increase catalytic activity, stability, lower immunogenic-
ty, and susceptibility to proteolytic processes.11,19–21
Protein engineering involves manipulating the protein
equence at the molecular level in order to change its
unction. The most common manipulations in the protein
equence are base pair cuts and exchanges. However, changes
n protein structure caused by oxidation or irreversible
eduction of disulﬁdes are also considered. One factor that
ontributed decisively to protein engineering was the develop-
ent of techniques that allow the determination of proteins
hree-dimensional structure at the atomic level. Among
hese techniques, more  emphasis is given to X-ray crys-
allography because of its high resolution (reaching < 1 A˚).
ore  recently, nuclear magnetic resonance (NMR) and Cryo-
lectron microscopy (cryo-EM) have also gained space as
lternative techniques for solving structures.22
Gene manipulation (e.g., codon replacement) by molecular
iology is able to modify protein structure in a speciﬁc manner.
mong the several techniques used for gene manipulation,
e highlight site-directed mutagenesis (SDM). This technique
llows rational protein engineering based on its three-
imensional structure.23,24 Using SDM, one can replace, delete,
r insert one or more  amino acids in the sequence of a protein.
xamples include the insertion of post-translational modiﬁ-
ation sites (glycosylation, acetylation, phosphorylation, etc.),
nhancement of kinetic characteristics by modiﬁcation of the
ctive site environment, and modiﬁcation of protein aggre-
ation paths.25–28 (Fig. 1) Biobetters generated by protein
ngineering and gene manipulation may present superior
haracteristics over the reference biopharmaceutical and rep-
esents the major growing class among biopharmaceuticals.
The reference recombinant protein is expressed in high
mounts and the molecular structure is determined at atomic
evels (crystallography or NMR). Afterwards, the protein is
nalyzed using bioinformatic tools and regions of interest
re identiﬁed. After gene manipulation by SDM, the modiﬁed
ecombinant protein (biobetter) is obtained.
pstream  processing  on  biopharmaceuticals
roduction
he manufacturing technology for biopharmaceuticals can
e divided into up- and downstream processes (Fig. 2).
pstream process is deﬁned as the microbial growth required
o produce biopharmaceuticals or other biomolecules and
nvolves a series of events including the selection of cell
ine, culture media, growth parameters, and process opti-
ization to achieve optimal conditions for cell growth and
iopharmaceutical production. The main goal of the upstream
rocess is the transformation of substrates into the desired
etabolic products.29 This requires well-controlled conditions
nd involves the use of large-scale bioreactors. Several factors
hould be considered such as the type of process (batch, fed-
atch, continuous, etc.) temperature, pH, and oxygen supplycontrol, sterilization of materials and equipment employed,
and maintenance of the environment to ensure it is free of
contaminating microorganisms.30
Biopharmaceuticals  produced  by  microorganisms
Bacteria
The use of protein biopharmaceuticals in human health
dates from the 19th century with the use of diphtheria anti-
toxin therapy.31 The antidote consists of immunoglobulins
extracted from the serum of immunized animals that rec-
ognize and neutralize the toxin (e.g., horse or sheep).31,32 In
fact, several antitoxins are available to treat envenomation by
snakes, scorpions, and wasps, or infections. However, the use
of non-human animal antibodies can cause hypersensitivity
of the patient to the animal serum, which is known as serum
sickness.33
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Culture at –80ºC
Plate or Stock Flask
Inoculum
preparation
Production
bioreactor
Centrifugation or filtration
(cell harvesting)
Precipitation and/or liquid liquid
extraction
Low resolution purification steps
Final
biophameceutical
Quality
control and 
packagingLiofilization
Formulation:
(Protein + Buffer +
Salt + Protectants)
High resolution purification steps
DiafiltrationViral
filtration
Polishing
cromatography
Viral
inactivationCromatography
Fig. 2 – The biopharmaceutical manufacturing technology ﬂowchart exemplifying the upstream and the downstream
bioprocess.
The 20th century experienced the use of several molecules
coming from animal sources such as insulin, growth hormone
(GH), glucagon, and asparaginase.34–36 However, the discov-
ery of the prion diseases related to the administration of hGH
revealed another potential risk associated with non-human
animal proteins. This reinforced the need for the produc-
tion of protein pharmaceuticals from other sources.37 At this
time, the biopharmaceutical industry looked at heterologous
expression of protein drugs by means of recombinant DNA
techniques in microorganisms.38
With the advances of molecular biology and recombinant
DNA, human proteins could be obtained by heterologous
expression using Escherichia coli, as well as other bacteria. The
classic example is human insulin, which is used to treat dia-
betes mellitus types I and II (DMI and DMII). Initially, insulin
was puriﬁed from the extracts of bovine and porcine pan-
creas. However, the process was expensive and many  cases of
immune responses caused by animal insulin in patients were
reported10,39 The human insulin gene was then isolated and
the human protein could be obtained by heterologous expres-
sion using E. coli (Fig. 3).
Filamentous  fungi
The great diversity of molecules produced by ﬁlamentous
fungi justiﬁes the exploitation of these organisms. In par-
ticular, the isolation and identiﬁcation of taxol-producing
endophytic fungi is a new and feasible approach to the pro-
duction of this antineoplastic drug. The development and
use of taxol-producing fungi have made signiﬁcant progress
worldwide.40 Taxol was produced by Fusarium oxysporum
grown in potato dextrose broth. In addition, the ﬁlamen-
tous fungus Aspergillus niger isolated from Taxus cuspidate was
found to produce taxol.41
Extracellular enzymes produced by ﬁlamentous fungi have
also been explored. -d-galactosidase (lactase – EC. 3.2.1 23) is
the enzyme responsible for the catalysis of lactose to glucoseand galactose. Global market for lactase has been increasing
signiﬁcantly due to its importance in lactose intolerance treat-
ment. Lactase is marketed in tablet or capsules to be used as a
food supplement for individuals intolerant to lactose before
the intake of milk or dairy products.42,43 Lactase also par-
ticipates in the galactooligosaccharides (GOS) synthesis with
applications in functional foods such as low-calorie foods and
as an additive in fermented dairy products, breads, and drinks.
GOS, a group of oligosaccharides, are not digestible and are
beneﬁcial to the human or animal body. The beneﬁts of GOS
ingestion arise from a population of biﬁdobacteria in the colon
that suppress the activity of putrefactive bacteria and reduce
the formation of toxic fermentation products, avoiding intesti-
nal constipation and increasing the production of vitamins B
complex.44,45
Another biological drug of importance in fungi is the
asparaginase enzyme. This enzyme is used for the treatment
of selected types of hematopoietic diseases such as acute lym-
phoblastic leukemia and non-Hodgkin lymphoma. As tumor
cells are dependent on the exogenous supply of asparagine for
their proliferation, the presence of the drug, which depletes
the bloodstream from asparagine, causes its selective death.
However, the drug, which is obtained from E. coli (ELSPARTM)
and Erwinia chrysanthemi, causes severe immunological reac-
tions. Thus, the fungi enzyme could provide an alternative to
the bacterial enzymes as an anti-tumoral agent as it presents
stability and optimum pH near physiological conditions.
Li et al. (2015)46 demonstrated the production of a
molecule with antifungal activity against a strain of Cytospora
chrysosperma by submerged fermentation in a shaker. The
active compound was obtained by extraction in organic sol-
vents, liquid chromatography, and thin-layer chromatography.
47Svahn et al. (2015) produced and isolated amphotericin B by
using a strain of Penicillium nalgiovense isolated from Antarc-
tica. It was the ﬁrst time that amphotericin B was isolated from
a different organism as it is usually isolated from Streptomyces
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Human insulin gene Bacterial plasmid
Recombinant plasmid
Bacterial transformation
and heterologous expression
Protein purification
(recombinant insulin)
Fig. 3 – Recombinant protein production. Using
recombinant DNA techniques, the target human gene can
be isolated and ligated to a vector (plasmid). The plasmid
containing the human gene is used to transform bacterial
cells, which are able to produce high amounts of the
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Table 1 – Biopharmaceuticals obtained from ﬁlamentous
fungi.
Compound Organism
Taxol Taxomyces andrenae
Beta-galactosidase A. foetidus
Lovastatin Monascus rubber,
A. terreus
l-asparaginase A. terreus
Ergot alkaloids Claviceps purpurea
Griseofulvin P. griseofulvum
Proteases Aspergillus specombinant protein.
odosus. Amphotericin B also showed a minimum inhibitory
oncentration of 0.125 mg/mL  against Candida albicans.
Collagenolytic proteases (KollagenaseTM) have been
irectly used in clinical therapy, including wound healing,
ciatica in herniated intervertebral discs, retained placenta,
nd as a pretreatment for enhancing adenovirus-mediated
ancer gene therapy.48 Another alkaline protease with col-
agenolytic activity was produced by A. niger LCF9 and the
nzyme hydrolyzed various collagen types without amino
cid release and liberated low molecular weight peptides of
49otential therapeutic use.
Carrez et al. (1990)50 detected the presence of interleukin-6
p to 25 ng/mL in a modiﬁed strain of A. nidulans expressing
he human interleukin-6. Years later, Yadwad and colleaguesPenicillium sp
Amphotericin B Penicillium nalgiovense
(1996)51 produced approximately 54 mg/L of interleukin-6 in
an air-lift fermenter with a recombinant strain of A. nidulans
and a medium supplemented with salts, fructose, and threon-
ine.
The production of biopharmaceuticals by ﬁlamentous
fungi is well studied, but the applicability of biomolecules pro-
duced by such organisms is still restricted by the high cost of
puriﬁcation of some molecules and by difﬁculty in ﬁlamentous
fungal cultivation (Table 1).52 Nonetheless, the use of ﬁlamen-
tous fungi for the production of compounds of interest is still
an interesting strategy.
Downstream  process:  Isolation  and  puriﬁcation
of  Biophamaceuticals
Downstream processing includes all steps required to purify
a biological product from cell culture broth to ﬁnal puri-
ﬁed product. It involves multiple steps to capture the target
biomolecule and to remove host cell related impurities (e.g.,
host cell proteins, DNA, etc.), process related impurities (e.g.,
buffers, leached ligands, antifoam, etc.) and product related
impurities (e.g., aggregates, fragments, clipped species, etc.).
Each puriﬁcation step is capable of removing one or more
classes of impurities.53,54 Downstream processing usually
encompasses three main stages, namely (i) initial recovery
(extraction or isolation), (ii) puriﬁcation (removal of most
contaminants), and (iii) polishing (removal of speciﬁed con-
taminants and unwanted forms of the target biomolecule that
may have formed during isolation and puriﬁcation).53,55,56
Initial recovery involves the separation between cell and
supernatant (broth clariﬁcation). For this purpose, the main
operations employed are centrifugation, ﬁltration, sedimen-
tation, and ﬂotation. If the target biomolecule is produced
extracellularly, the clariﬁed broth is submitted to concentra-
tion (e.g., ultraﬁltration) followed by puriﬁcation. For example,
secreted and soluble proteins in the culture media of P. pas-
toris can be directly recovered by centrifugation. Samples can
then be concentrated and the target protein puriﬁed from the
supernatant by processes such as ultraﬁltration, precipitation,
and/or chromatography.57 For intracellular biomolecules, the
cells harvested must be submitted to lysis (e.g., high-pressure
homogenizer, sonication, passing through mills, etc.) followed
by clariﬁcation to remove cell debris. The target biomolecule
is puriﬁed from the clariﬁed cell homogenate (usually by pre-
cipitation and/or chromatography). In cases where proteins
 i c r o56  b r a z i l i a n j o u r n a l o f m
are expressed as inclusion bodies (as some recombinants pro-
duced by E. coli), an extra step of protein refolding (buffer
exchange) is required. These additional steps signiﬁcantly
contribute to increases in production time and costs for intra-
cellular biomolecules.58
Efﬁcient recovery and puriﬁcation of biopharmaceuticals
have been referred as a critical part of the production process.
Puriﬁcation process must be robust, reliable, easily scaled-up,
and capable of removing both processes- and product-related
impurities to ensure product safety. The achieved purity,
the speed of process development, overall recovery yield,
and throughput are some of the main key parameters that
must be taken into consideration during downstream process
development.55 To reach the stringency of purity required in
the biopharmaceutical industry, sometimes exceeding 99%,
chromatography steps are usually required. Chromatography
allows for high resolution and has traditionally been the
workhorse for protein puriﬁcation and polishing.53,56 How-
ever, chromatography has also been the major cost center in
puriﬁcation processes, mainly due to media cost and relatively
long cycle times. In addition, the biopharmaceutical indus-
try still faces practical limitations in terms of throughput and
scalability.55
Chromatography
Different strategies based on sequences of classical chro-
matography have been described for nucleic acids, peptides,
and proteins puriﬁcation. In fact, chromatography is a very
effective puriﬁcation technique with a wide range of indus-
trial applications and currently represents the favorite choice
due to its high resolution capacity.56 The separation principle
in chromatography is based on the differences in the afﬁnity of
the species carried by a ﬂuid mobile phase toward a solid sta-
tionary phase. When a sample is introduced and transported
by the eluent along the column, some of its components
will have more  powerful interactions with the stationary
phase than others, generating concentration proﬁles that will
percolate the chromatographic column at different speeds.
The less retained species will elute earlier from the column
than the most retained ones, eventually allowing the collec-
tion of the products of interest with a high purity degree.59
Based on the interaction between the solid stationary phase
and biomolecules, chromatographic techniques can be sum-
marized into ﬁve classes: (i) afﬁnity, (ii) ion-exchange, (iii)
hydrophobic interactions, (iv) size exclusion, and (v) mixed-
mode chromatography.60
Afﬁnity chromatography simulates and exploits natural
biological processes such as molecular recognition for the
selective puriﬁcation of target proteins.61 This class of chro-
matography is probably the only technique currently available
that is capable of addressing key issues in high-throughput
proteomics and scale-up.62 The most common example of
an afﬁnity process is protein-A chromatography, which has
been applied for over a decade in industrial and academic
settings for the capture and puriﬁcation of antibodies.60 Sim-
ilarly, protein-L may possibly come to play a role in antibody
fragments puriﬁcation.59 Another afﬁnity-based strategy well
established for recombinant proteins puriﬁcation is the use
of fusion tags, which are amino acid sequences attached to b i o l o g y 4 7 S (2 0 1 6) 51–63
recombinant proteins with selective and high afﬁnities for
a chemical or biological ligand immobilized on a chromato-
graphic column. In particular, the polyhistidine (xHis) tag has
been frequently used to purify recombinant proteins due to
its binding capacity toward divalent metal cations.60 Despite
the fact that afﬁnity methods usually eliminate puriﬁcation
steps, increase yields, and downsize capital equipment, they
do present some drawbacks, particularly regulatory ones since
complete withdrawal of leached ligands is a requirement.61
Traditional choices in chromatographic set ups include
particle-based resins, batch mode operation, and packed
columns. In order to address the drawbacks from these
standard parameters, some process alternatives are attracting
the pharmaceutical industry, especially the chromatographic
separations based on simulated moving bed (SMB), expanded
bed adsorption (EBA), and single block monolith columns.
SMB chromatography is the preferred choice for enan-
tiomer separation of synthetic drugs in pharmaceutical
industry. However, just recently, its use made a signiﬁcant rise
in biotechnology companies, especially for protein refolding
and continuous downstream process.63 The system presents
multiple small chromatographic columns sequentially con-
nected and operated with countercurrent ﬂow of ﬂuids.
Simulated moving comes from the periodical switch of mul-
tiport inlets/outlets from column to column, in the direction
of ﬂuid ﬂow, which gives the impression that the column bed
is moving. These inlet/outlet valves (feed, desorbent, rafﬁnate,
and extract) are positioned in a way that minimize dead zones,
allow desorbent recycling, optimize product recovery, and
function as semi-continuous mode.64 Especially for refolding,
SMB together with the recycling of aggregates lead to a the-
oretical yield of 100%, excluding the folding equilibrium as a
limiting factor for productivity.65 Nevertheless, SMB  is more
complex to implement and requires a higher investment cost.
EBA chromatography is a 3-in-1 process intended to cap-
ture the product directly from the cell suspension, combining
clariﬁcation, concentration, and initial puriﬁcation. The bot-
tom feed from the EBA system creates a ﬂow that gradually
expands the resin and form a stable particle gradient.66 This
gradient consists of particles of different size ranges and dif-
ferent densities, which requires a narrow range of calculated
ﬂow rates. All adsorbents in direct contact with the feed-
stock may bind to cells/cell debris, disrupting the gradient
and reducing recovery. This issue is addressed with studies
on adsorption pH to identify conditions with maximum prod-
uct adsorption and minimum cell adhesion.67 Several studies
have shown the value of EBA. It efﬁciently removes precip-
itates and captures target proteins from refold pools of E.
coli-based production68 and it promotes enhanced recovery of
Human Epidermal Growth Factor from E. coli homogenate and
Pichia pastoris culture medium.67
Particle-based resins rely on mass transfer mainly through
diffusion, requiring long times for large biomolecules. On
the other hand, the single block monolith column has
interconnected channels that transfer mass mainly through
convection, which allows for high ﬂow velocity. In addi-
tion, monolith does not have the packing step and tolerates
the passage of air, reducing costs, and time with packing
validation and repacking/replacing solid phase due to air inter-
ruption. Other signiﬁcant advantages are easy scale-up due to
b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 7 S (2 0 1 6) 51–63 57
Table 2 – Unit operations for continuous downstream process.
Centrifugation Filtration Precipitation/crystallization Chromatography
Split-bowl centrifuge Single pass tangential ﬂow Tubular reactor Expanded bed
Disk nozzle centrifuge Batch  topped off Simulated moving bed
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ﬂMembrane cascades 
Diaﬁltration
ow independent of dynamic binding and compatibility with
everal organic, polymer-based, and inorganic media.69 The
isadvantage of higher buffer consumption can be decreased
ith the SMB  set up, which can also be combined with single
se technology. Monoliths are widely applied to the recovery
f proteins such as coagulation factor IX (ion exchange)70 and
gG (afﬁnity chromatography)29 from a variety of cell culture
ncluding P. pastoris71 and E. coli.69
lternative  separation  techniques
ith a burgeoning biotechnology market, there is an ongoing
earch for new and improved alternatives to chromatography
n an effort to lower costs and improve yields, while maintain-
ng high product purity.56 Several promising alternatives have
een described in literature including afﬁnity precipitation,
igh-performance tangential ﬂow ﬁltration, ﬁltration strate-
ies based on thiophilic and afﬁnity interactions, two-phase
queous systems, high-gradient magnetic ﬁshing, preparative
lectrophoresis, and isoelectric focusing.53,55,56,58
Magnetic separation with immunocapture supports stands
mong the techniques used in puriﬁcation kits, but just
ecently its application to industrial scale showed viable paths.
he initial high costs of the beads from the kits were surpassed
ith new materials and broader size dispersion and bind-
ng capacity, without decreasing batch-to-batch consistency.
ub-micron superparamagnetic particles of coated magnetite
rystals can be functionalized according to the desired selec-
ivity. These particles have been used for the puriﬁcation of
nzymes and inclusion bodies.29Filtration with ion-exchange membranes substitutes ﬂow-
hrough chromatography for polishing steps. They remove
ost-cell proteins, nucleic acids, and viruses with increased
ow rates, reduce buffer consumption and time, when
Table 3 – Examples of therapeutic native proteins obtained by p
Biopharmaceutical Commercial name 
Botulinum toxin type A Botox 
Botulinum toxin type B Myoblock 
Collagenase Collagenase, santyl 
l-Asparaginase Elspar 
PEG-l-asparaginase Oncaspar 
* Adapted from Leader et al., 2008.Annular
compared to traditional polishing. Hydrophobic interac-
tion membranes can remove dimers and aggregates from
monoclonal antibody production and substitute more  chro-
matography steps.72
General  trends
The aim of downstream process should be to deliver the
highest yield of the purest product at the shortest time/cost.
However, traditional processes and quality control does
not bring the efﬁciency needed to keep pace with current
upstream production. To address current issues, some general
trends emerge as most relevant including single use mod-
ules, continuous production, process analytical technology,
and quality by design.73
The disposable units are compatible with continuous mode
and bring faster routine operation because no cleaning or
cleaning/validation has to be performed.73 Continuous pro-
cesses generally result in higher productivity, less buffer
consumption, and smaller footprint. A general end-to-end
continuous process can be accomplished by perfusion cell
reactors coupled with a continuous capture step, inte-
grated with some of the downstream technologies described
in Table 2. A recent and extensive review on continuous
downstream processing of biopharmaceuticals describes and
discusses each set up option in detail.64
Process consistency over time can be assured with the aid
of process analytical technology (PAT) and Quality by Design
(QbD) concepts described in the International Council for Har-
monisation of Technical Requirements for Pharmaceuticals
for Human Use (ICH) guidelines. QbD preconizes that the
product is the process. Therefore, it is essential to know the
critical process parameters and link them with critical mate-
rial attributes to predict and adjust their impact on critical
uriﬁcation from natural sources.
Host organism Clinical use
Clostridium botulinum Several kinds of dystonia;
cosmetic procedures
C. botulinum Several kinds of dystonia;
cosmetic procedures
Clostridium histolyticum Treatment of the chronic
dermal ulcers and burned
areas
E. coli Acute lymphocytic
leukemia (ALL)
E. coli Chemically modiﬁed
asparaginase (PEGylated) to
the ALL treatment
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Table 4 – Examples of therapeutic recombinant proteins obtained by heterologous expression in E. coli.
Biopharmaceutical Other commercial names Clinical use
Aldesleukin (interleukin-2) Proleukin Melanoma and renal cancer treatment
Anakinra (interleukin 1 (IL1) receptor antagonist) Antril, Kineret Rheumatoid arthritis treatment
Calcitonin (salmon calcitonin) Fortical Post menopausal osteoporosis treatment
Denileukin diftitox (interleukin-2 and Diphtheria
toxin fusioned)
Ontak  T-cell lymphoma treatment
Filgrastim (analog to the granulocyte
colony-stimulating factor)
Neupogen Neutropenia treatment (as consequence
of AIDS, chemotherapy, bone-among
others)
Filgrastim pegylated Neulasta Neutropenia treatment (as consequence
of AIDS, chemotherapy, bone- marrow
transplantation, among others)
Growth hormone (GH) Genotropin, Humatrope,
Norditropin, Norivitropin,
Nutropin, Omnitrope,
Protropin, Siazen,
Serostim, Valtropin
Prader-Willi and Turner syndromes
Glucagon Glucagon Hypoglycemia
Glucarpidase (bacterial carboxypeptidase G2) Voraxaze Control of methotrexate conc. in patients
with deﬁcient renal function
Insulin (inhalation) Exubera Diabetes mellitus treatment
Insulin (fast-acting) Lispro Diabetes
Insulin (zinc extended) Lente, Ultralente Diabetes mellitus treatment
Interferon-2a Roferon-A Chronic hepatitis C. chronic myelogenous
leukemia, hairy cell leukemia, Kaposi’s
sarcoma
Interferon-2b Intron A Chronic hepatitis C. chronic myelogenous
leukemia, hairy cell leukemia, Kaposi’s
sarcoma
Interferon-2b pegylated Peg-intron Chronic hepatitis C. chronic myelogenous
leukemia, hairy cell leukemia, Kaposi’s
sarcoma
Interferon-1b Betaseron Multiple sclerosis
Interferon-1b Actimmune Chronic granulomatous disease, severe
osteopetrosis
Mecasermin (insulin-like growth factor 1) Increlex GH and IGF1 deﬁciencies
Mecasermin rinfabate (insulin-like growth factor I
and its binding protein IGFBP-3)
iPlex  GH and IGF1 deﬁciencies
Nesiritide (B-type natriuretic peptide) Natrecor Acute decompensated
heart failure (ADHF) treatment
Oprelvekin (interleukin 11) Neumega Prevention of severe thrombocytopenia
(patients in chemotherapy)
OspA (Outer surface protein A fragment from
Borrelia burgdorferi)
LYMerix  Lyme disease vaccine
Palifermin (truncade keratinocyte growth factor) Kepivance Treatment of oral mucositis in (patients
undergoing chemotherapy)
Parathyroid hormone Preos, Preotact Treatment of osteoporosis and
hypoparathyroidism
Pegvisomant, modiﬁed GH (prevent GH binﬁng to
receptor)
Somavert Acromegaly treatment
Ranibizumab (Mab fragment) Lucentis Age related macular degeneration
Reteplase (plasminogen activator) Rapilysi Acute myocardial infarction treatment
Somatropin, tasonermin Humatrope hGH deﬁciency treatment
Tasonermin (cytokine) Beromun Soft sarcoma treatment
Urate oxidase, PEGylated Krystexxal Gout
Teriparatide. Parathyroid hormone Forteo Severe osteoporosis treatment
The data were obtained from manufacturer pages and from16 http://www.biopharma.com.
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Fig. 4 – Commercial biopharmaceutical products approved
from 2005 to 2015. Dark green bars represent monoclonal
antibody related products and non-related total
recombinant proteins are represented in red. The data used
concerning the number of biopharmaceutical approvals are
available at biopharma biopharmaceutical products16
(http://www.biopharma.com/approvals).b r a z i l i a n j o u r n a l o f m i 
uality attributes of the ﬁnal product. Processes developed
nder QbD knowledge contain design spaces instead of sin-
le value or extremely narrow parameters; values inside the
esign space results in good product performance and brings
he necessary ﬂexibility to continuous processing.74 How-
ver, knowledge of the process requires process analytical
echnology (PAT) tools that include analytical chemistry and
athematical and statistical modeling/analysis. Among the
ptions, near infrared spectroscopy and principal component
nalysis are trending choices for analytical and mathematical
ools, which can be applied to several steps.75
lobal  consumer  market  of  microbial
iopharmaceuticals
n 1982, human insulin was the ﬁrst recombinant protein
hat was FDA approved for use in humans as a biophar-
aceutical product.10,39 In the 1980s, the biopharmaceutical
ndustry experienced a signiﬁcant growth in the production
nd approval of recombinant proteins including interferons
IFN , , and ) and growth hormones. In the 1990s, the ﬁrst
onoclonal antibodies (MAb) and related products experi-
nced an extraordinary growth, and in 2015, these products
epresented two-thirds of the products approved for commer-
ial use in the world according to the Biotrack database76Fig. 4).
Currently, the total market sales from microbial recombi-
ant products reached approximately $50 billion, representing
ne-third of the total sales of biopharmaceuticals. The choice
Table 5 – Examples of therapeutic recombinant proteins obtain
Biopharmaceutical Comm
Albumin Recombumin 
Hepatitis B surface
antigen
Engerix,  Fendrix
Recombivax HB
Hepatitis B surface
antigen and hepatitis A virus inactibated
Ambirix, Twinrix
Hirudine Reﬂudan, Revas
HPV vaccine Gardasil 
HPV surface antigens Silgard 
Glucagon like peptide 1, Liraglutide Victoza 
Insulin Humulin, Novol
Mixtard, Insulat
Actraphane,
Insulin aspart; insulin glulisine; insulin lispro
(fast-acting insulin analog)
Novolog (aspart)
Humalog (lispro
Insulin detemir (long-acting insulin) Levemir 
Isophane insulin (intermediate -acting insulin) Humulin N 
Platelet Derived Growth Factor-BB Regranex 
Parathyroid hormone Preos, Preotact 
Rasburicase Ranibizumab, Fa
Somatropin (GH) Valtropin 
Sargramostim Leukine 
The data were obtained from manufacturer pages and from16 http://www.of microorganism in the production of biopharmaceuticals
relies on many  factors including low cost production, easy
manipulation, and propagation, and molecular biology meth-
ods. Some of the most important biopharmaceuticals obtained
by natural sources or by heterologous expression are shown in
Tables 3–5.
ed by heterologous expression in S. cerevisiae.
ercial name Clinical use
Manufacture of human therapeutics
Hepatitis B vaccine
 Hepatitis A and B vaccine
c Anticoagulant
HPV vaccine
HPV vaccine
Diabetes mellitus treatment
in, Protaphane,
ard, Actrapid,
Diabetes mellitus treatment
, Apidra (glulisine),
)
Diabetes mellitus
Diabetes mellitus
Diabetes mellitus
Treatment of neuropathic, chronic,
diabetic ulcer
Treatment of osteoporosis and
hypoparathyroidism
sturtec Treatment of leukemia, lymphoma and
tumor lysis syndrome
GH deﬁciency treatment
Neutropenia treatment (as consequence
of AIDS, chemotherapy, bone- marrow
transplantation, among others)
biopharma.com.
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Table 6 – Top-10 biopharmaceuticals based on sales revenues in 2015. According to Gal77 and Igea78.
Rank Product® Product type Production system Company Use 2015 sales (US$
million)
Patent expiry
U.S.A E.U.
01 Humira (Adalimumab) Anti-TNF  MAb CHO AbbVie (U.S.) Inﬂammatory
diseases
14,021 2016 2018
02 Enbrel (Etanercept) Anti- TNF  MAb CHO Amgen (U.S.)
Pﬁzer (U.S.)
Takeda Pharm.
(Japan)
Inﬂammatory
diseases
9027  2028a 2015
03 Remicade (Inﬂiximab) Anti- TNF  MAb SP2/0 Johnson & Johnson
(U.S.)
Merck (U.S.)
Mitsubishi T. (Japan)
Inﬂammatory
diseases
8957  2018 2014
04 Lantus (Insulin glargine) Insulin analog E. coli Sanoﬁ (France) Diabetes 7209 2014 2014
05 Avastin (Bevacizumab) Anti-VEGF MAb CHO Roche (Switzerland) Cancer 6905 2019 2022
06 Herceptin (Trastuzumab) Anti-HER2 MAb CHO Roche (Switzerland) Cancer 6754 2019 2015
07 Prevnar family Polysaccharides
conjugated to
diphtheria protein
Streptococcus
pneumoniae and
Corynebacterium
diphtheriae
Pﬁzer  (U.S.) Pneumococcal
vaccine
6245 2026 n.a.
08 MabThera/Rituxan
(Rituximab)
Anti-CD20 MAb CHO Roche (Switzerland) Cancer and
autoimmune
diseases
5827 2015 2013
09 Neulasta (PEGﬁlgrastim) Recombinant G-CSF E.  coli Amgen (U.S.) Cancer-
related
infections
4715 2015 2017
10 Lucentis (Ranibizumab) Anti-VEGF FAb E. coli Novartis
(Switzerland)
Roche (Switzerland)
Macular
degeneration
3630  2020 2022
a The main patent on Enbrel (Etanercept) was originally expected to expire on October 2012, but owing to a ﬁling loophole, Amgen secured an additional 16-year period of exclusivity. n.a., data not
available. CHO, Chinese Hamster Ovary mammalian cell. SP2/0, Mouse myeloma cells.
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Biopharmaceuticals are revolutionary in the pharmaceuti-
al industry. According to global revenues, 10 biotechnological
elated products ﬁgured among the top-25 best-selling drugs
n 2015; 4 of them produced by microorganisms77,78 (Table 6).
hese biopharmaceuticals are marketed by leading pharma-
eutical companies primarily located in U.S.A, Japan, and
urope and comprise a narrow scope of treatment proﬁle, with
ost drugs for the treatment and management of inﬂamma-
ory diseases (e.g. rheumatoid arthritis) and cancer.
Patents for cloning and production of several original-
eneration (branded) biopharmaceuticals have expired or will
xpire within the next years (Table 6). Similar to chemi-
al drugs, once the patent of a biological product is expired
he marketing of biosimilars and generics is possible.79
hese patent expirations, combined with rising healthcare
osts and population aging worldwide are paving the way
or the development of biosimilars and biobetters, opening
ew commercial opportunities.80,81 Many  biosimilars are cur-
ently under development and these follow-on products will
nevitably play substantial competition and an increasing role
n healthcare in upcoming years.79,82 In Brazil the scenario is
odest, but considering the global panel and recent govern-
ent incentive for the national biopharmaceutical industry
evelopment, we  expect to see more  patents in the near future
nd also novel opportunities for biosimilars and biobetters.
onclusion  and  future  trends
ew technological advancements are continuously made to
mprove the discovery, rational modiﬁcation, production, and
uriﬁcation of biopharmaceuticals. Innovative strategies to
dentify different species of microorganisms from the Brazil-
an biodiversity must be investigated targeting the discovery
f alternative hosts for heterologous expression.
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